Mirtazapina Almus (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic activity. Its strong antihistamine effect also contributes to sedation, supporting patients with depressive insomnia.

The appropriate dose of Mirtazapina Almus is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to professional medical guidance.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors, and its potent antihistamine activity. This profile often results in strong sedative effects and weight gain, which can be advantageous for patients with insomnia or loss of appetite, but may be less desirable for those concerned about metabolic side effects.

Mirtazapina Almus should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Mirtazapina Almus is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include the potential for suicidal thoughts or behaviors, especially early in treatment, severe allergic reactions such as anaphylaxis, agranulocytosis, and rare skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for any signs of these conditions.

Mirtazapina Almus is contraindicated in patients who have taken monoamine oxidase inhibitors within the past 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment where dose adjustment is not feasible. It should also be used with caution in the elderly and in patients with a history of bipolar disorder.